Searchable abstracts of presentations at key conferences in endocrinology

ea0034p147 | Clinical practice/governance and case reports | SFEBES2014

Non islet cell tumour hypoglycaemia: management strategies for a rare and challenging condition

Kalathil Dhanya , Roughneen Simon , Shah Momin , Akram Ali , Zaidi Reza , Purewal Tejpal , Ahmad Aftab , Weston Philip

We previously reported a case of non islet cell tumour hypoglycaemia (NICTH) due to increased ‘big’-IGF2 production in a lady with haemangiopericytoma (HAP). We now describe the challenges in managing this lady who had recurrent, disabling hypoglycaemia requiring frequent hospitalisation.This patient presented with symptomatic hypoglycaemia 15 years after the diagnosis of parasaggital HAP. At presentation she had tumour recurrence with liver an...

ea0098c34 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Comparative assessment of 111in-octreotide scintigraphy, 68GA-DOTATOC PET/CT and 18F-FDG PET/CT in the staging and management of neuroendocrine tumors (NETs)

Zaidi Ali , Chia Brendan , Zhou Marilyn , Ladua Gale , Ravi Pavithraa , Bloise Ingrid , Harsini Sara , Wilson Don , Benard Francois , Martineau Patrick , Loree Jonathan M

Background: Accurate imaging is essential for NETs. 111In-octreotide scintigraphy, 68Ga-DOTATOC PET/CT and 18F-FDG PET/CT are the most commonly used modalities. This study compared the three modalities to ascertain the added value of newer functional imaging approaches.Methods: A retrospective review was performed on patients who underwent 68Ga-DOTATOC PET/CT and 18F-FDG PET/CT between 07/2018 and 03/2023 as part of a clinical trial at BC Cancer. Patient...

ea0098c3 | Clinical – Chemo/SSA/Biologics | NANETS2023

Real-world evidence of lenvatinib use for treatment of metastatic neuroendocrine neoplasms

Paulo Solar Vasconcelos Joao , Eduardo Nunez Rodrigues Jose , Zaidi Ali , Jafari Helia , Krishnan Tharani , Gill Sharlene , Tan Ann , Le Dan , Chan Theresa , Yu Simon , Paul McGhie John , Lim Howard , Singh Simron , Michael Loree Jonathan

Background: Metastatic neuroendocrine neoplasms (NENs) constitute a heterogeneous group of uncurable cancers with limited treatment options. Lenvatinib is an oral multiple kinase inhibitor that showed activity in gastroenteropancreatic neuroendocrine tumors in the phase II Talent Trial at a starting dose of 24 mg per day. Although a confirmatory phase III study was never conducted, the drug is available for use off-label.Methods: We retrospectively revie...